S-1: MapLight Therapeutics IPO: CNS Drug Developer Seeks Public Listing

Sentiment:

Initial Public Offering Registration Statement 19 September 2025 8:11 PM

📋All filings for Maplight Therapeutics, INC

Clinical-stage biopharmaceutical company MapLight Therapeutics files S-1 for initial public offering to advance CNS disorder therapies, including lead candidates for schizophrenia and Alzheimer's psychosis.

Delay expectedThe Phase 2 ML-004 clinical trial was placed on a partial clinical hold by the FDA in January 2022 with respect to the enrollment of adolescents, which was removed in October 2024.The Investigational New Drug (IND) application for ML-007C-MA was put on clinical hold by the FDA in May 2024 due to nonclinical findings, which was lifted in July 2024.

Capital raiseThe company is undertaking an Initial Public Offering (IPO) of its common stock, as detailed in this S-1 filing.In July 2025 and September 2025, the company issued and sold an aggregate of 210,033,285 shares of Series D Preferred Stock for gross proceeds of $200.0 million.Since its inception, the company has raised approximately $511.0 million from leading venture capital funds, healthcare investors, and foundation grants.The company explicitly states that the net proceeds from this offering, together with existing cash, cash equivalents, and short-term investments, will be insufficient to fund any of its product candidates through regulatory approval, and it anticipates needing to raise additional capital to complete development and commercialization.

Worse than expectedThe company has incurred substantial net losses of $77.6 million in 2024 and $52.2 million in the first half of 2025, indicating a worsening financial trend.An accumulated deficit of $251.6 million as of June 30, 2025, highlights significant historical financial underperformance.The filing explicitly states that recurring losses from operations and financial condition raise substantial doubt about the company's ability to continue as a going concern.The company will require substantial additional financing beyond the IPO proceeds to complete the development and commercialization of its product candidates, indicating a precarious financial position.

Summary

MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for debilitating central nervous system (CNS) disorders.
The lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, initially for schizophrenia and Alzheimer's disease psychosis (ADP).
ML-007C-MA has been evaluated in four Phase 1 trials involving 270 healthy participants and over 1,500 doses, demonstrating potential for good tolerability and convenient dosing (onceor twice-daily, no fasting required).
The company is currently conducting ZEPHYR, a Phase 2 trial for schizophrenia, with topline results expected in the second half of 2026.
VISTA, a Phase 2 trial for ADP, is also underway, with topline results anticipated in the second half of 2027.
A second product candidate, ML-004, a 5-HT1B/1D agonist, is being developed for social communication deficit and/or irritability in autism spectrum disorder (ASD), with Phase 2 IRIS trial results expected in the second half of 2026.
Preclinical programs include ML-021 for Parkinson's disease motor deficits (IND-enabling studies expected H2 2026) and ML-009 for hyperactivity, impulsivity, and agitation-related disorders (preclinical candidate nomination expected 2026).
The company has incurred substantial net losses: $77.6 million in 2024, $55.7 million in 2023, and $52.2 million for the six months ended June 30, 2025, leading to an accumulated deficit of $251.6 million as of June 30, 2025.
MapLight Therapeutics has raised approximately $511.0 million from inception through venture capital, healthcare investors, and foundation grants.
The net proceeds from this offering, combined with existing cash, cash equivalents, and short-term investments, are expected to fund operations through an unspecified future date, but additional capital will be required to complete product development and commercialization.

Sentiment

Score: 4

Explanation: The company has promising clinical candidates and a strong scientific foundation in areas of high unmet medical need, but faces significant financial challenges with substantial recurring losses, a large accumulated deficit, and a stated need for considerable additional capital to reach commercialization. The clinical holds, though resolved, highlight regulatory hurdles. The IPO provides capital but doesn't eliminate the long-term funding need.

Positives

The company has a robust pipeline with three clinical-stage candidates (ML-007C-MA, ML-004) and two preclinical programs (ML-021, ML-009) targeting significant CNS disorders.
ML-007C-MA demonstrated a favorable safety and tolerability profile in Phase 1 studies, with low rates of moderate treatment-emergent adverse events (TEAEs) and no serious or severe adverse events, supporting convenient onceor twice-daily dosing without fasting.
Preclinical data for ML-007 showed strong activation of both M1 and M4 receptors, suggesting potential to improve positive, negative, and cognitive symptoms of schizophrenia, and improved spatial and social memory in an Alzheimer's disease mouse model.
ML-004 demonstrated statistically significant improvements in sociability and aggression in preclinical ASD animal models.
The management team is highly experienced in neuroscience research, drug development (involved in >75 programs), regulatory affairs, and commercialization (>25 product approvals/expansions).
Scientific founders, Karl Deisseroth and Robert Malenka, are world-renowned neuroscientists who developed groundbreaking technologies like optogenetics and STARmap.
The company has successfully raised approximately $511.0 million from leading venture capital funds, healthcare investors, and foundation grants since its inception.
Antipsychotic therapies are a protected class under Medicare Part D, mandating open access, which could support commercial adoption if ML-007C-MA is approved.

Negatives

The company has a limited operating history and no commercialized products, making it difficult to evaluate future viability.
MapLight Therapeutics has incurred substantial and increasing net losses, totaling $77.6 million in 2024, $55.7 million in 2023, and $52.2 million for the first six months of 2025.
An accumulated deficit of $251.6 million as of June 30, 2025, indicates significant historical losses.
The company will require substantial additional financing beyond the proceeds of this offering to complete clinical development and commercialization of its product candidates.
Recurring losses and financial condition raise substantial doubt about the company's ability to continue as a going concern.
Clinical drug development is a lengthy, expensive, and inherently unpredictable process, with a high risk of failure.
The ML-007C-MA IND was placed on clinical hold by the FDA in May 2024 due to nonclinical findings, though it was lifted in July 2024.
The Phase 2 ML-004 clinical trial was on a partial clinical hold by the FDA from January 2022 to October 2024 regarding adolescent enrollment.
Product candidates may fail to achieve sufficient market acceptance due to competition from existing standards of care and potential side effects.
Interim, topline, and preliminary clinical data are subject to change as more patient data become available and undergo verification.
Changes in product candidate manufacturing or formulation may lead to additional costs or delays.
The company's focus on CNS disorders faces historical challenges in drug development, including reliance on subjective patient-reported outcomes and the placebo effect.
Significant reliance on third parties (CROs, CMOs, clinical investigators) introduces risks if they fail to perform or comply with regulations.
The company faces intense competition from pharmaceutical and biotechnology companies with greater resources and established market presence.
Uncertainty exists regarding pricing, coverage, and reimbursement for future products, which could limit revenue.
The market for product candidates may be smaller than anticipated, impacting commercial success.
Operating as a public company will incur increased costs and demands on management, potentially diverting resources.
The company's ability to use net operating loss carryforwards and other tax attributes may be limited due to potential ownership changes.

Risks

Limited operating history and no history of commercializing products may make it difficult to evaluate the company's future viability.
Substantial and increasing losses are anticipated for the foreseeable future, and the company may never achieve or maintain profitability.
The company will require substantial additional financing beyond the IPO proceeds, and failure to obtain it could delay, limit, reduce, or terminate product development or commercialization efforts.
Recurring losses from operations and financial condition raise substantial doubt about the company's ability to continue as a going concern.
Inability to successfully identify, develop, and commercialize any product candidates or experiencing significant delays could materially and adversely affect the business.
Preclinical and clinical drug development is a lengthy, expensive, and uncertain process, potentially leading to additional costs or delays.
The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming, expensive, and inherently unpredictable, potentially harming the business if approvals are not obtained.
The company is subject to various U.S. federal, state, and foreign healthcare laws and regulations, which could increase compliance costs and lead to significant fines or liability for non-compliance.
Reliance on third parties (independent clinical investigators, contracted laboratories, CROs) to conduct preclinical studies and clinical trials poses risks if they fail to perform or meet deadlines.
Competitive products may reduce or eliminate the commercial opportunity for product candidates if competitors develop more rapidly or offer more effective/safer technologies.
Future success depends on the ability to retain key executives and attract, retain, and motivate qualified personnel.
Inability to obtain and maintain sufficient intellectual property protection or if the scope of protection is not broad enough, competitors could commercialize similar products.
Being an emerging growth company and a smaller reporting company may result in reduced disclosure and governance requirements, potentially making common stock less attractive to investors.
Management will have broad discretion in the use of IPO proceeds, which may not align with investor expectations or increase investment value.
The trading price of common stock may be volatile, and purchasers could lose all or part of their investment.
Executive officers, directors, and principal stockholders have the ability to significantly influence matters submitted to stockholders for approval.
No intention to pay dividends on common stock, limiting returns to stock value appreciation.
Sales of a substantial number of shares in the public market after lock-up periods could cause the stock price to fall.
Purchasers of common stock in the IPO will suffer immediate dilution of their investment.
Employees, independent contractors, consultants, collaborators, principal investigators, CROs, suppliers, and vendors may be improperly classified or engage in misconduct or improper activities.
Information technology systems or data of the company or third parties could be compromised, leading to adverse consequences including regulatory actions, litigation, and reputational harm.
Business disruptions from natural disasters, disease outbreaks, geopolitical actions, or other events could seriously harm future revenue and financial condition.
Patent terms may be inadequate to protect the competitive position of product candidates for an adequate amount of time.
Changes in patent law in the United States and other jurisdictions could diminish the value of patents.
Inability to protect intellectual property rights throughout the world due to varying legal protections.
Potential involvement in lawsuits to protect or enforce patents or other intellectual property, which could be expensive, time-consuming, and unsuccessful.
Third parties may claim infringement, misappropriation, or violation of their intellectual property rights, preventing or delaying development and commercialization.
Claims challenging the inventorship or ownership of patents and other intellectual property.
Inability to protect the confidentiality of trade secrets, materially adversely affecting the value of technology.
Uncertainty related to pricing, coverage, and reimbursement for product candidates, potentially limiting commercial success.
Current and future healthcare reform legislation or regulation may increase the difficulty and cost to obtain coverage and commercialize product candidates.
Disruptions at the FDA and other government agencies caused by funding shortages, staffing limitations, or global health concerns could hinder timely development, approval, or commercialization.
If the FDA does not conclude that certain product candidates satisfy the requirements for the Section 505(b)(2) regulatory approval pathway, approval could take significantly longer and cost more.
Subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations, which could impair ability to compete.
Exclusive forum provisions in corporate charter documents could limit stockholders' ability to obtain a favorable judicial forum for disputes.
Anti-takeover provisions in corporate charter documents and under Delaware law could make an acquisition more difficult and may prevent attempts by stockholders to replace or remove current management.

Future Outlook

MapLight Therapeutics expects to incur significant and increasing expenses and net losses for the foreseeable future as it advances its current and future product candidates through preclinical and clinical development and seeks regulatory approval. The company anticipates needing to raise substantial additional capital to complete the development and commercialization of its product candidates. Topline results for the Phase 2 ZEPHYR trial (schizophrenia) and IRIS trial (ASD) are expected in the second half of 2026, while topline results for the Phase 2 VISTA trial (ADP) are expected in the second half of 2027. The company also plans to complete IND-enabling studies for ML-021 and nominate a preclinical candidate for ML-009 in 2026, continuing to leverage its platform to expand its pipeline and opportunistically engage in strategic collaborations.

Management Comments

"We believe our deep understanding of these causal links between the modulation of defined neural circuits and the resulting changes in disease-specific behaviors will enable us to develop therapeutics that can deliver efficacy, safety, tolerability and ease-of-use advantages to patients and prescribers."
"Based on our clinical and preclinical data, we believe that ML-007C-MA has demonstrated the potential to be a well-tolerated treatment option with convenient dosing, while achieving or exceeding CSF exposures expected to result in improvement across key symptom domains."
"We believe targeting muscarinic receptors represents a compelling therapeutic alternative to dopaminergic antipsychotics for the treatment of schizophrenia and ADP."
"We believe that the combination approach of activating both M1 and M4 muscarinic receptors in the CNS, paired with precision-matched antagonism of muscarinic receptors in the periphery, is the key to achieving the optimal therapeutic profile for the muscarinic agonist class."
"We believe ML-004 has the potential to be a compelling therapy to address social communication deficits for which there are no approved therapies and/or ASD-related irritability symptoms, while avoiding the serious side effects often observed with current therapeutic options."
"We believe the commercial potential for ML-007C-MA, if approved, in schizophrenia or ADP is substantial given prevalence of the conditions, severity of unmet medical need and the chronic nature of both conditions."

Industry Context

The company operates in the biotechnology and pharmaceutical industries, characterized by rapidly advancing technologies and intense competition. There is a significant unmet medical need in schizophrenia, affecting over 20 million globally, and Alzheimer's disease psychosis (ADP), affecting approximately 40% of 7 million U.S. Alzheimer's patients. Current standard-of-care atypical antipsychotics for schizophrenia primarily treat positive symptoms, have significant side effects (e.g., EPS, metabolic issues), and lead to poor adherence. For ADP, there are no approved therapies, and off-label antipsychotics have modest efficacy and serious side effects, including increased mortality risk in elderly patients. The recent FDA approval of COBENFY, an M1/M4 muscarinic agonist, for schizophrenia marks a novel mechanism in decades, demonstrating muscarinic approaches can improve both positive and negative symptoms without typical antipsychotic side effects, though COBENFY has its own side effect profile and inconvenient dosing. For autism spectrum disorder (ASD), there are no FDA-approved therapies for core symptoms like social communication deficits, and existing treatments for irritability (atypical antipsychotics) have serious side effects. The global antipsychotic market is projected to grow from $14 billion in 2024 to over $20 billion by 2030, with new entrants potentially gaining market share through improved safety and tolerability. Antipsychotics are a protected class under Medicare Part D, ensuring open access.

Comparison to Industry Standards

ML-007C-MA aims to differentiate from existing and emerging muscarinic agonists like COBENFY (xanomeline/trospium) by offering an improved safety and tolerability profile and more convenient dosing (onceor twice-daily, no fasting) through synchronized pharmacokinetics of its agonist and antagonist components, addressing COBENFY's reported high rates of cholinergic side effects and inconvenient dosing regimens (e.g., 3-8 day titration, fasting requirements).
Preclinical studies showed ML-007 had greater than two-fold higher peak intrinsic activity compared to xanomeline (COBENFY's agonist) in M1/M4 GTPgS assays and approximately 10-fold greater potency by dose in various in vivo models (e.g., amphetamine-induced hyperlocomotion).
ML-007, unlike xanomeline, demonstrated improvement in spatial and social memory in a mouse model of Alzheimer's disease, suggesting a potential cognitive benefit that other muscarinic agonists have not adequately powered to assess in clinical trials.
ML-004 is being developed to address social communication deficits in ASD, a core symptom for which there are currently no FDA-approved pharmaceutical treatments, distinguishing it from atypical antipsychotics like ABILIFY (aripiprazole) and RISPERDAL (risperidone) which are only approved for ASD-associated irritability and carry serious side effects.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Chief Financial Officer	Jonathan Gillis	Vishwas Setia	March 2024	Vishwas Setia appointed; Jonathan Gillis transitioned to Chief Administrative and Accounting Officer.
Chief Administrative and Accounting Officer	NA	Jonathan Gillis	March 2024	Transitioned from Chief Financial Officer role.
General Counsel	NA	Kristopher L. Hanson	April 2023	Appointment to the role.
Director	NA	Nanna Lneborg, Ph.D.	July 2025	Appointment to the Board.
Director	Robert Malenka, M.D., Ph.D. (served 2018-July 2025)	Robert Malenka, M.D., Ph.D.	September 2025	Reappointed to the Board.
Director	Peter Bisgaard	NA	September 17, 2025	Resigned from the Board.
Director	NA	Maria Walker	February 2024	Appointment to the Board.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Structure	The Board of Directors will be divided into three classes with staggered three-year terms upon the closing of this offering.	Upon closing of this offering	May delay or prevent a merger, acquisition, or other change in control, and make it more difficult for stockholders to replace management.
Director Removal	Directors may be removed by stockholders only for cause upon the affirmative vote of at least 66 2/3% of the outstanding common stock.	Upon closing of this offering	Increases the difficulty for stockholders to remove directors and effect changes in management.
Director Appointment/Vacancies	The authorized number of directors may be changed only by resolution of the Board, and vacancies and newly created directorships will be filled by a majority vote of the directors then in office.	Upon closing of this offering	Centralizes control over Board composition with the existing Board, potentially limiting stockholder influence.
Voting Rights	Stockholders will not have cumulative voting rights, meaning holders of a majority of common stock can elect all directors.	Upon closing of this offering	Concentrates voting power in the hands of majority stockholders, potentially limiting minority stockholder representation.
Stockholder Action	All stockholder actions must be effected at a duly called meeting of stockholders, eliminating the right of stockholders to act by written consent without a meeting.	Upon closing of this offering	Makes it more difficult for stockholders to take action quickly or outside of scheduled meetings.
Special Meetings	Only the Chairman of the Board, Chief Executive Officer, or the Board of Directors (by majority resolution) may call a special meeting of stockholders.	Upon closing of this offering	Restricts the ability of individual stockholders or groups to call special meetings.
Stockholder Proposals/Nominations	Stockholders seeking to present proposals or nominate candidates for election as directors must provide timely advance written notice and comply with specified requirements.	Upon closing of this offering	Establishes formal procedures that may limit the ability of stockholders to introduce business or nominate directors without prior planning and compliance.
Preferred Stock Issuance	The Board of Directors will have the authority to issue up to an unspecified number of shares of preferred stock in one or more series, with rights and preferences designated by the Board, without further stockholder approval.	Upon closing of this offering	Provides the Board with flexibility for acquisitions and other corporate purposes, but could also be used to deter hostile takeovers or dilute common stockholders' voting power.
Code of Business Conduct and Ethics	A Code of Business Conduct and Ethics will be adopted, applicable to all employees, executive officers, and directors.	Upon pricing of this offering	Establishes ethical guidelines and compliance standards for all personnel, enhancing corporate integrity.
Non-Employee Director Compensation Policy	A formal non-employee director compensation policy was adopted, providing for cash retainers and equity compensation (stock options) for Board and committee service.	Upon pricing of this offering	Standardizes and formalizes compensation for non-employee directors, aligning their interests with stockholders through equity awards.
Board Committees	The Board has established an audit committee, a compensation committee, and a nominating and corporate governance committee, with members meeting independence requirements.	Upon closing of this offering	Enhances corporate oversight and compliance with listing standards, promoting accountability in financial reporting, executive compensation, and governance practices.
Director and Officer Indemnification	Amended and restated certificate of incorporation and bylaws limit the liability of directors and officers to the fullest extent permitted by Delaware law and provide for indemnification.	Upon closing of this offering	Aims to attract and retain qualified directors and officers by reducing personal liability, but may discourage lawsuits against them.
Exclusive Forum Provisions	The Court of Chancery of the State of Delaware is designated as the exclusive forum for certain corporate actions, and federal district courts for Securities Act claims.	Upon closing of this offering	Aims to ensure consistent judicial interpretation of Delaware law and federal securities law, but may limit stockholders' choice of forum and increase costs for certain claims.

Legal Proceedings

No material legal proceedings are currently pending or, to the best of the company's knowledge, threatened as of June 30, 2025.

Related Party Transactions

Series B, B-1, C, and D Preferred Stock financings involved significant investments from entities affiliated with NFLS Beta Limited, Clock LLC (affiliated with George Pavlov and Robert Malenka), Catalyst4, Inc., Novo Holdings A/S (affiliated with Jim Trenkle), Forbion Growth Opportunities Fund III Coperatief U.A. (affiliated with Nanna Lneborg), the Robert C. Malenka Living Trust, and Christopher A. Kroeger.
In October 2023, the company entered into an Assignment and Assumption Agreement with Stellaromics, Inc., transferring an exclusive worldwide license for STARmap technology in exchange for 9.8% of Stellaromics' outstanding capital stock (fair value $1.1 million). Christopher A. Kroeger (CEO and Director) and George Pavlov (Director) are on Stellaromics' board, and Catalyst4, Inc. (largest stockholder of MapLight) holds 78.3% of Stellaromics' outstanding capital stock as of June 30, 2025.
An advisor agreement with Robert Malenka, M.D., Ph.D. (co-founder and Director) provides monthly payments of $11,667 ($140,000 annually) for his service on the company's scientific advisory board.
The spouse of Anatol Kreitzer, Ph.D. (Chief Discovery Officer) was employed by the company from November 2023 to April 2025, with an annual salary between $225,000 and $275,000 and RSU grants.
The IPO includes a directed share program reserving up to a percentage of shares for sale to certain directors, officers, employees, and others.
The company has entered into or expects to enter into indemnification agreements with each of its directors and executive officers.

Stakeholder Impact

**Shareholders**: Potential for significant dilution from future capital raises and the IPO. Existing stockholders will experience immediate dilution. Returns are currently limited to stock price appreciation as no dividends are anticipated. Concentration of ownership by executive officers, directors, and principal stockholders could influence corporate decisions. Lock-up agreements will restrict immediate resale of shares for many existing holders.
**Employees**: Equity compensation plans (2019 Plan, 2025 Plan, ESPP) provide incentives. Employment is at-will. Severance and Change in Control Plan offers benefits upon qualifying termination. Potential for increased headcount and operational expansion as the company grows. Risk of improper classification of employees/contractors.
**Customers/Patients**: Potential for novel therapeutic options for debilitating CNS disorders (schizophrenia, ADP, ASD) where there is significant unmet need and current treatments have limitations or serious side effects. The success of product candidates could significantly improve patient lives.
**Suppliers/Creditors**: Reliance on third-party manufacturers and CROs means their performance and compliance are critical. The company's recurring losses and need for additional financing could impact its ability to meet obligations if funding is not secured. Creditors face risks associated with the company's going concern doubt.
**Regulatory Bodies**: The company is subject to extensive and evolving regulations from the FDA and other authorities, requiring significant compliance efforts and costs. Clinical holds and regulatory scrutiny can impact development timelines and approvals.

Next Steps

Report topline results from the Phase 2 ZEPHYR trial for schizophrenia in the second half of 2026.
Report topline results from the Phase 2 VISTA trial for Alzheimer's disease psychosis (ADP) in the second half of 2027.
Report topline results from the Phase 2 IRIS trial for autism spectrum disorder (ASD) in the second half of 2026.
Explore potential strategies for further development of ML-004 based on the results from the IRIS trial.
Complete IND-enabling studies for the preclinical program ML-021 (M4 antagonist for Parkinson's disease) in the second half of 2026.
Nominate a preclinical candidate for the ML-009 program (GPR52 PAM for hyperactivity, impulsivity, and agitation-related disorders) in 2026.
Advance ML-007C-MA efficiently through registrational trials for the treatment of schizophrenia and ADP.
Expand the potential of ML-007C-MA by exploring and pursuing additional indications, such as cognitive impairment associated with Alzheimer's disease, bipolar disorder, agitation associated with Alzheimer's disease, psychoses associated with other neurodegenerative diseases, and dyskinesias.
Expand the pipeline by leveraging the versatility and reproducibility of the company's discovery platform to bring additional product candidates into the clinic.
Maximize the value of the pipeline and platform by opportunistically engaging in strategic collaborations.
Build global commercialization capabilities internally or through third-party relationships if product candidates receive regulatory approval.
File one or more registration statements on Form S-8 under the Securities Act to register shares subject to outstanding stock options and shares issued or issuable under equity plans.

Key Dates

Date	Description
November 2018	Company incorporated as Alvarado Therapeutics, Inc.
February 21, 2019	2019 Equity Incentive Plan adopted by the Board and stockholders.
August 2019	Company changed its name to MapLight Therapeutics, Inc.
June 18, 2020	Asset Purchase Agreement entered with NeuroSolis, Inc. to acquire M1/M4 agonist molecules and associated intellectual property.
February 2021	Series B preferred stock financing commenced.
July 2021	Additional 1,528,654 shares of Series B Preferred Stock sold for $1.8 million.
January 2022	Phase 2 ML-004 clinical trial placed on partial clinical hold by the FDA regarding adolescent enrollment.
March 25, 2022	Board and Series B Preferred Stock holders waived milestone event for additional Series B shares.
March 30, 2022	Additional 18,004,153 shares of Series B Preferred Stock sold for $21.2 million.
August 2022	Second amendment to the Redwood City lease, increasing office and lab space and extending the term to June 2031.
October 2022	Series B-1 preferred stock financing with Clock LLC for $12.0 million.
June 1, 2023	New European unitary patent system took effect.
July 5, 2023	Initial closing of Series C preferred stock financing for $50.0 million.
August 2023	Redwood City lease increased space to 13,734 square feet.
October 2023	Restated Series C Purchase Agreement and Amended Additional Closing for Series C shares ($55.0 million gross proceeds). Entered into Assignment and Assumption Agreement with Stellaromics, Inc.
December 8, 2023	National Institute of Standards and Technology published Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights.
January 1, 2024	Statutory cap on the Medicaid drug rebate eliminated by the American Rescue Plan Act of 2021.
February 23, 2024	Maria Walker appointed to the Board of Directors.
March 2024	Amended Restated Series C Purchase Agreement, with milestone purchasers waiving milestones and additional Series C shares sold for $120.0 million. Vishwas Setia appointed Chief Financial Officer.
April 2024	Burlington, Massachusetts office lease commenced.
May 2024	ML-007C-MA IND placed on clinical hold by the FDA due to nonclinical findings.
June 2024	U.S. Supreme Court decision in Loper Bright Enterprises v. Raimondo overturned the Chevron doctrine.
July 2024	ML-007C-MA IND clinical hold lifted.
October 2024	Partial clinical hold on Phase 2 ML-004 clinical trial for adolescent enrollment removed by the FDA.
November 2024	Entered into a license agreement with Vanderbilt University.
June 2025	Issued 447,006 shares of common stock to NeuroSolis upon achievement of a specified milestone. Initiated Phase 2 ZEPHYR trial for schizophrenia and Phase 2 VISTA trial for ADP.
July 4, 2025	The One Big Beautiful Bill Act (OBBBA) signed into law, expected to reduce Medicaid spending and enrollment.
July 2025	Series D preferred stock financing (Tranche 1 Initial Closing) for $188.2 million gross proceeds. Nanna Lneborg, Ph.D. appointed to the Board of Directors.
September 2025	Series D preferred stock financing (Tranche 1 Additional Closing) for $11.8 million gross proceeds. Board adopted non-employee director compensation policy and Severance and Change in Control Plan, effective upon IPO pricing. Board approved grant of options and RSUs to employees, directors, and founders, effective upon IPO pricing. Robert Malenka, M.D., Ph.D. reappointed to the Board of Directors.
September 17, 2025	Peter Bisgaard resigned from the Board of Directors.
H2 2026	Expected topline results for ZEPHYR (schizophrenia) and IRIS (ASD) trials. Expected completion of IND-enabling studies for ML-021. Expected nomination of a preclinical candidate for ML-009.
H2 2027	Expected topline results for VISTA (ADP) trial.
2031	Redwood City office and laboratory lease term ends. ML-007 composition of matter patents and use patents expected to expire.
2032	ML-007 composition of matter patents expected to expire.
2039	State net operating loss carryforwards begin to expire. Federal research and development tax credits begin to expire.
2040	ML-004 use patents expected to expire.
2042	ML-007C-MA combination patents and ML-004 IR/ER composition patents expected to expire.
2044	ML-007C-MA PCT application patents and ML-009 PCT application patents expected to expire.
2045	ML-007 salts and crystalline polymorphs provisional application patents expected to expire.

Recommendation

hold

MapLight Therapeutics presents a compelling long-term opportunity given its innovative scientific platform and clinical candidates targeting high-need CNS disorders. The positive Phase 1 data for ML-007C-MA and preclinical results for ML-004 are encouraging, and the experienced management team adds credibility. However, the company is in early clinical stages, faces substantial and increasing net losses, and has an accumulated deficit of $251.6 million, raising significant going concern doubts. The explicit need for substantial additional financing beyond the IPO proceeds indicates a prolonged period of cash burn before potential commercialization. While the IPO provides a capital infusion, the inherent risks of drug development, regulatory hurdles (as evidenced by past clinical holds), and intense market competition warrant caution. A 'hold' recommendation reflects a balanced view, acknowledging the significant upside potential but emphasizing the considerable financial and execution risks that require careful monitoring of future clinical milestones and financial stability.

Keywords

Biopharmaceutical, CNS Disorders, Schizophrenia, Alzheimer's Disease Psychosis, Autism Spectrum Disorder, ML-007C-MA, ML-004, M1/M4 Muscarinic Agonist, 5-HT1B/1D Agonist, Clinical Stage, IPO, Drug Development, Neuroscience, Biotech, Pharmaceuticals

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.